

Small interfering RNA targeting N-cadherin regulates cell proliferation and migration in enzalutamide-resistant prostate cancer

CHENG-HSIN LU^{1-3*}, CHUN-HSIEN WU^{2,4,5*}, PEI-FANG HSIEH^{2,6}, CHEN-YU WU^{2,7},
WADE WEI-TING KUO^{2,4}, CHIEN-HUI OU^{8*} and VICTOR CHIA HSIANG LIN^{2,7*}

¹Division of Urology, Penghu Hospital, Penghu 880001; ²Division of Urology, Department of Surgery, E-Da Hospital;

³Division of Urology, Department of Surgery, E-Da Cancer Hospital; ⁴Department of Chemical Engineering and Institute of Biotechnology and Chemical Engineering, ⁵Department of Nursing, I-Shou University, Kaohsiung 824005;

⁶Department of Medical Laboratory Science and Biotechnology, Chung-Hwa University of Medical Technology,

Tainan 717302; ⁷School of Medicine, College of Medicine, I-Shou University, Kaohsiung 824005;

⁸Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704302, Taiwan, R.O.C.

Received July 26, 2021; Accepted November 3, 2021

DOI: 10.3892/ol.2022.13210

Abstract. Enzalutamide is one of the options for treating patients with castration-resistant or metastatic prostate cancer. However, a substantial proportion of patients become resistant to enzalutamide after a period of treatment. Cells in these tumors typically exhibit increased proliferative and migratory capabilities, in which N-cadherin (CDH2) appear to serve an important role. In the present study, by up- and downregulating the expression of CDH2, the possible effects of CDH2 on the prostate cancer cell line LNCaP were investigated. Male sex hormone-sensitive LNCaP cells treated with 10 μ M enzalutamide were named LNCaP enzalutamide-resistant (EnzaR) cells. Reverse transcription-PCR, western blotting and

immunofluorescence staining were used to measure CDH2, E-cadherin, α -SMA, Snail and Slug expression. Transfection with the pCMV-CDH2 plasmid was performed for CDH2 upregulation, whilst transfection with small interfering RNA (siRNA)-CDH2 was performed for CDH2 downregulation. MTT and Cell Counting Kit-4 assays were used to evaluate the proportion of viable cancer cells. Subsequently, gap closure assay was performed to evaluate the migratory capability of both LNCaP and LNCaP EnzaR cell lines. CDH2 expression was found to be increased in LNCaP EnzaR cells compared with that in LNCaP cells. CDH2 overexpression increased cell viability and migration in both LNCaP and LNCaP EnzaR cell lines. By contrast, the opposite trend was observed after CDH2 expression was knocked down. CDH2 expression also showed a high association with that of four epithelial-mesenchymal transition markers, which was confirmed by western blotting. Based on these results, it was concluded that knocking down CDH2 expression using siRNA transfection mediated significant influence on LNCaP EnzaR cell physiology, which may be a potential therapeutic option for prostate cancer treatment.

Correspondence to: Professor Victor Chia Hsiang Lin, Division of Urology, Department of Surgery, E-Da Hospital, 1 Yida Road, Kaohsiung 824005, Taiwan, R.O.C.

E-mail: victorlin0098@gmail.com

Professor Chien-Hui Ou, Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Shengli Road, Tainan 704302, Taiwan, R.O.C.

E-mail: donou1969@yahoo.com.tw

*Contributed equally

Abbreviations: CDH2, N-cadherin; EnzaR, enzalutamide-resistant; siRNA, small interfering RNA; EMT, epithelial-mesenchymal transition; PCa, prostate cancer; ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; α -SMA, α -smooth muscle actin; WB, western blotting

Key words: N-cadherin, enzalutamide resistance, prostate cancer, proliferation, migration

Introduction

Prostate cancer (PCa) is one of the most prevalent malignancies in men, the severity of which is heterogeneous, ranging from indolent to lethal (1). The main therapeutic strategy for metastatic PCa and castration-naïve recurrence is androgen deprivation therapy (ADT) (2). By reducing androgen levels, ADT blocks the activation of the androgen signaling cascade and androgen receptor (AR)-mediated gene expression (3). However, after a period of ADT, evolution to castration-resistant prostate cancer (CRPC) frequently occurs (4). Treatment options for CRPC are limited, since the majority of the second-generation anti-androgen therapeutic

agents target the AR (5). One option for treating this type of cancer is enzalutamide, which was approved by the Food and Drug Administration in 2018 (6). It is an AR antagonist that also blocks its nuclear translocation and AR-mediated DNA binding (7). Despite the availability of this second-generation anti-androgen, a proportion of tumors will develop resistance to enzalutamide (8). By investigating causes and characteristics underlying enzalutamide resistance in PCa, novel therapeutic strategies can be discovered.

One reported cause of therapeutic resistance is epithelial-mesenchymal transition (EMT), which is a fundamental process of embryogenesis (9). Resistance to oxaliplatin has been previously found in colon carcinoma epithelial cell lines with mesenchymal morphology (10). In addition, loss of epithelial phenotype have also been reported to associate with resistance to paclitaxel in ovarian carcinoma epithelial cell lines (11). In a similar manner, EMT has been found to promote the conversion to androgen-independent PCa (12). EMT is also a key process in promoting cancer cell invasiveness, since it disrupts cell-to-cell or cell-to-extracellular matrix adherence (13). It serve a role in the metastasis of certain malignancies by inducing the loss of E-cadherin expression whilst increasing N-cadherin expression (13). A number of factors have been documented to be involved in this mechanism (14). Snail, Slug and Twist are among the number of E-cadherin transcriptional repressors that can induce the epigenetic silencing of the E-cadherin promoter (14). Furthermore, α -smooth muscle actin (α -SMA) is a myofibroblast marker that can be used as a marker of cancer-associated fibroblasts (15). α -SMA-positive myofibroblasts can promote the metastasis of oral tongue squamous cell carcinoma cells by promoting EMT (15). Previous studies have also shown that regulating particular markers, such as Snail and Slug, may facilitate prostate cancer metastasis (16,17).

Cadherin-2 (CDH2), also known as N-cadherin, is highly expressed in the nervous system and vascular endothelium (18). It is a member of the cadherin family and is involved in various intracellular signaling pathways, such as the PI3K/Akt signaling pathway (19,20). It also serves an important role in EMT. CDH2 expression has been found to serve a role in several human cancers, including bladder, colorectal, lung and gastric cancer (20-23). Since it can weaken intercellular interactions and form homophilic interactions with other CDH2-expressing tissues, CDH2 has been shown to be a key component in mediating cancer cell invasion and metastasis (24,25). In PCa, CDH2 expression is typically higher in patients with high-grade primary tumors or lymph node metastasis compared with that in patients with low-grade tumors (26,27). In addition, CDH2 expression was found to positively correlated with the Gleason score (26,27). This increased CDH2 expression is sufficient for EMT as well as prostate cancer invasion and metastasis (25). Furthermore, it was found to be necessary for the proliferation of CRPC cells and causes CRPC development (12,25). In a previous study performed by Tanaka *et al* (25), N-cadherin was present in a number of castration-resistant cell lines but was absent in the hormone-sensitive LNCaP cell line (25). The difference in molecular expression between castration-resistant and hormone-sensitive cell lines suggests CDH2 to be a possible target for CRPC treatment.

In the present study, two different prostate cancer cell lines, LNCaP and enzalutamide-resistant LNCaP cells (LNCaP EnzaR cells), were chosen. Compared with LNCaP cells, LNCaP EnzaR cells display a similar morphology but heterogeneous proliferative characteristics (28). LNCaP EnzaR cells also display increased metastatic colonization potential in a number of clinically relevant organs *in vivo*, including bone, brain and the adrenal glands (28). By comparing the properties of these two cell lines, the aim was to explore a novel strategy to manipulate prostate cancer cell physiology. The expression levels of CDH2 in these two PCa cell lines were first measured. Subsequently, CDH2 expression was upregulated before assessing its possible effects on cell viability, migratory capability and the expression of EMT markers in LNCaP and LNCaP EnzaR cells. Finally, to investigate the influence of CDH2 on cell viability and migration, the same assays were performed on cells with LNCaP and LNCaP EnzaR cells transfected with small interfering RNA (siRNA)-CDH2 cells to downregulate CDH2.

Materials and methods

Cell culture. LNCaP cells were obtained from the American Tissue Culture Collection and cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) at 37°C with 5% CO₂. LNCaP cells were exposed to different concentrations of enzalutamide (1-10 μ M; cat. no. S1250; Selleck Chemicals). At each concentration of enzalutamide, the cells were grown in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) under 5% CO₂ at 37°C for 1 week to allow them to acclimatize and then proliferate for a ≥ 6 months. Since there is no consensus on the concentrations required to generate EnzaR cells, the cells were treated under 5% CO₂ at 37°C with 10 μ M enzalutamide in accordance with previous studies (28,29). The LNCaP EnzaR cells generated from 10 μ M enzalutamide treatment were maintained in the aforementioned media containing 5 μ M enzalutamide.

Transfection. To create the pCMV-CDH2 plasmid, the CDH2 (accession no. NM_001792) open reading frame (ORF) sequence was cloned into the Human-Tagged ORF Clone plasmid (cat. no. RC207170; Origene Technologies, Inc.). Cells were cultured in six-well plates and treated with the pCMV-CDH2 (2 μ g/ml) (cat. no. RC207170; Origene Technologies, Inc.) or pCMV-GFP plasmid (2 μ g/ml) (cat. no. PS100010; Origene Technologies, Inc.). Plasmid transfections were performed using FuGENE HD Transfection Reagent (Roche Diagnostics, Inc.) and incubated for 37°C and 5% CO₂ for 24 h according to the manufacturer's protocols. LNCaP and LNCaP EnzaR cell lines were each divided into the following three groups: Untreated cells (pCMV-GFP:-, pCMV-CDH2:-); empty vector-transfected cells (pCMV-GFP:+, pCMV-CDH2:-); and CDH2 transfected cells (pCMV-GFP:-, pCMV-CDH2:+).

For CDH2 knockdown, the *CDH2* gene was silenced using ON-TARGETplus CDH2 siRNA SMARTpool (siRNA-CDH2; cat. no. L-011605-00-0005), which was purchased from Dharmacon, Inc.; Cytiva. The sequences of CDH2 siRNA and the ON-TARGETplus non-targeting pool (siRNA-control;

Dharmacon, Inc.; Cytiva; cat. no. D-001810-10-05) are listed in Table I. CDH2 siRNAs (5 pmol) were transfected into the cells using Lipofectamine RNAiMAX reagent (Invitrogen; Thermo Fisher Scientific, Inc.) under 5% CO₂ at 37°C for 24 h. LNCaP and LNCaP EnzaR cell lines were also divided into the following groups: Untreated cells (siRNA-control:-, siRNA-CDH2:-), siRNA-control-transfected cells (siRNA-control:+, siRNA-CDH2:-) and siRNA-CDH2-transfected cells (siRNA-control:-, siRNA-CDH2:+).

After 24 h of transfection, the cells were subjected to reverse transcription PCR (RT-PCR) and western blot (WB) analysis.

RT-PCR. Total RNA was isolated using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). In total, 1 µg total RNA was subjected to reverse transcription into cDNA using SuperScript™ III First Strand Synthesis System for RT-PCR (Invitrogen; Thermo Fisher Scientific, Inc.). From 5 µg RNA, cDNA was prepared using oligo dT (50 µM) and 10 mM dNTP. For the PCR reactions, 1 µl oligo dT primer and 1 µl 10 mM dNTP mix were added to 8 µl RNA, incubated for 5 min at 65°C and then placed on ice for ≥1 min. Subsequently, 10 µl cDNA synthesis mix was added [2 µl 10X RT buffer, 4 µl 25 mM MgCl₂, 2 µl 0.1 M DTT, 1 µl RNase OUT™ (40 U/µl) and 1 µl SuperScript™ III RT (200 U/µl)] to each RNA/primer mixture and incubated for 50 min at 50°C, followed by reaction termination at 85°C for 5 min. For each reaction, 10X PCR buffer (cat. no. 18067-017; Invitrogen; Thermo Fisher Scientific, Inc.), MgCl₂ (50 mM), dNTP mix (10 mM), cDNA, Taq DNA polymerase (5 U/µl) and each pair of primers were added. The resultant product was stored at -20°C. Reactions containing 5 µl 10X PCR buffer, 1.5 µl 50 mM MgCl₂, 1 µl 10 mM dNTP mix, 2 µg cDNA, 10 µM of each pair of primers, 0.4 µl Taq DNA polymerase and 38.1 µl DEPC water were first incubated for initial denaturation at 94°C for 2 min. PCR was then performed for 35 cycles. For all PCR programs, an annealing temperature of 55°C for 30 sec and denaturation and extension temperatures of 94°C and 72°C, respectively, for 30 sec.

RNA was used as a template for reverse transcription (Invitrogen; Thermo Fisher Scientific, Inc.) followed by PCR analysis using specific primers for N-cadherin (forward, 5'-AGCCTGGAACATATGTGATGA-3' and reverse, 5'-CCA TAA AACGTCATGGCAGTAA-3'); GAPDH forward, 5'-ATGTGTCCGTCGTGGATCTGAC-3' and reverse, 5'-AGA CAACCTGGTCCTCAGTGTAG-3'. The expression levels of total RNA were normalized to the expression of gene GAPDH (assay ID, Hs03929097_g1; Thermo Fisher Scientific, Inc.). DNA (0.5 µg/lane) was visualized using gel electrophoresis on a 2% agarose gel stained with SafeView™ Classic staining (Applied Biological Materials, Inc.).

WB. The cells were lysed using RIPA buffer (50 mM Tris/pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 1 mM sodium fluoride and 1 mM EDTA). A BSA standard curve was used to detect protein concentration, which was used to analyze cell lysates. Protein lysates (20 µg) were separated by 10% SDS-PAGE and then transferred onto polyvinylidene fluoride membranes (EMD Millipore). After blocking the membranes with 5% non-fat milk for 1 h at 25°C, they were

Table I. CDH2 siRNA and siRNA-control target sequence.

Oligonucleotide	Target sequence 1 (5'-3')	Target sequence 2 (5'-3')	Target sequence 3 (5'-3')	Target sequence 4 (5'-3')	Cat. no.
ON-TARGETplus CDH2 siRNA SMARTpool	GUGCAACAGUAUAC GUUAA	GGACCCAGAU CGAU AUAUG	CAUAGUAGCUAAUC UAACU	GACAGCCUCUCUC AAUGU	L-011605-00-0005
ON-TARGETplus Non-targeting pool	UGGUUUACAUGUC ACUAA	UGGUUUACAUGUG UGUGA	UGGUUUACAUGUUU UCUGA	UGGUUUACAUGUUU UCCUA	D-001810-10-05
CDH2, N-cadherin; siRNA, small interfering RNA.					

incubated with 1:2,000 dilutions of specific primary antibodies against E-cadherin (CDH1; cat. no. ab53033; Abcam), CDH2 (cat. no. ab18203; Abcam), α -SMA (cat. no. ab5694; Abcam), Snail (cat. no. ab85931; Abcam), Slug (cat. no. sc-166476; Santa Cruz Biotechnology, Inc.) and β -actin (cat. no. A5441; Sigma-Aldrich; Merck KGaA) at 4°C overnight. The membranes were then washed in Tris-buffered saline with 0.1% Tween 20 and incubated with HRP-conjugated secondary antibodies (cat. no. ab6721; Abcam; 1:4,000) for 1 h at room temperature. The Pierce™ ECL Western Blotting Substrate enhanced chemiluminescence system (cat. no. 32209; Thermo Fisher Scientific, Inc.) was used for visualization and detection using a Multi-function Gel Image System (cat. no. MQIS-21-C2; Tangshan Top Bio Technology, Co., Ltd.).

Immunofluorescence staining. To perform immunocytochemistry analysis, 1×10^4 cells grown in two-well chamber slides were transfected and incubated for 24 h at 37°C in a humidified atmosphere with 5% CO₂. Cells were washed with PBS two times, fixed and permeabilized with 99.9% ice-cold methanol for 15 min at 4°C before blocking with 2% BSA in PBS for 1 h at 4°C. Cells were then incubated with primary antibodies against CDH2 (cat. no. ab18203; Abcam; 1:2,000) for 1 h at 4°C, washed with PBS three times and incubated with Alexa Fluor® 488-labeled, species-specific secondary antibodies (cat. no. ab150077; Abcam). Before mounting, the slides were washed with PBS, counterstained with 1.5 μ g/ml DAPI for nuclear staining at room temperature for 1 h and then observed under a fluorescent microscope (Olympus Corporation; magnification, x200) using the ipwin32 (Image-Pro Plus version no. 6; Media Cybernetics, Inc.) software.

MTT assay. Cells were grown in RPMI containing 10% FBS, which were then plated at a density of 5×10^4 cells/well in 24-well plates overnight and incubated with pCMV-CDH2 for 24 h, each at 37°C and 5% CO₂. Cell viability was assessed using MTT assay. After transfection for 24 h, MTT solution was added into each well and incubated for 3 h. Then, 50 μ l 5 mg/ml MTT solution was added into each well containing 500 μ l medium and incubated at 37°C for 3 h, followed by the addition of 500 μ l isopropyl alcohol to dissolve the reduced formazan product. The absorbance at 590 nm in each well was measured using a spectrophotometer (Sunrise-Basic; Tecan Group, Ltd.) before cell viability was examined. Values calculated represent the mean OD₅₉₀ \pm SD from \geq three independent reaction wells.

Cell Counting Kit-8 (CCK-8) assay. Cells were seeded into 96-well plates and allowed to grow to 60-75% confluence before treatment. Cells were then transfected with pCMV-GFP, siRNA-control, pCMV-CDH2 or siRNA-CDH2 in RPMI 1640 with 10% FBS at 37°C for 24 h. Cell viability was evaluated using the CCK8 assay (cat. no. ab228554; Abcam). Afterwards, the medium was aspirated, rinsed with PBS and treated with CCK-8 at 10 μ l/well for 2 h at 37°C. Absorbance was measured at 450 nm using a spectrophotometer (Sunrise-Basic; Tecan Group, Ltd.). The percentage of LNCaP and LNCaP EnzaR cell viability in cell lines, as well as their transfected cell lines, was calculated using the following formula: Viability (%) = (optical density of sample/optical density of control) \times 100.

Gap closure assay. Cell migration by LNCaP and LNCaP EnzaR cells was examined using a gap closure assay with ibidi Culture-Insert 2 Well system (Cat.No:80209, Ibidi, Gräfelfing, Germany) according to the manufacturer's protocols. Cells were seeded overnight at a concentration of $1.75 \times 10^4/100 \mu$ l/well in each individual compartment of the Ibidi culture insert. The culture plate was then filled with RPMI complete medium as previously described (30,31), before the Ibidi culture inserts were removed. A live cell imaging light microscope (Leica AF 6000 LX; Leica Microsystems, GmbH; magnification, x200) was used to monitor and capture images of the cells at 0 h and after 24 h of incubation at 37°C. For each image, areas between one side of the gap and the other were measured using Quantity One software (version 4.6.6; Bio-Rad Laboratories, Inc.). Migration rate was quantified by dividing the change in wound area by the time spent in migration and was expressed as a percentage. To quantify the effects of CDH2 overexpression or knockdown on migration, the percentage of gap closure after 24 h was analyzed.

Statistical analysis. Each experiment was performed \geq three times and representative images are shown. The results were expressed as the mean \pm standard error of the mean (SEM). Statistical analyzes with GraphPad Prism 9 (GraphPad Software, Inc.) were performed using one-way ANOVA followed by Tukey's post hoc test as appropriate. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

CDH2 expression is increased in LNCaP EnzaR cells. To determine the role of CDH2 in LNCaP and LNCaP EnzaR cells, RT-PCR was used to first measure the expression levels of CDH2. CDH2 expression was markedly higher in the LNCaP EnzaR cell line, which was almost absent in the sensitive LNCaP cell line (Fig. 1A). Protein expression of CDH2 was next evaluated by WB, where markedly higher CDH2 expression levels were also observed in LNCaP EnzaR cells compared with those in LNCaP cells (Fig. 1B). In addition, immunofluorescence staining revealed high CDH2 protein expression levels in LNCaP EnzaR cells, suggesting that LNCaP EnzaR cells express CDH2 at higher levels compared with that in LNCaP cells (Fig. 1C). CDH2 was found to be localized at the surfaces of LNCaP EnzaR cells, but exhibited low expression levels in the hormone-sensitive LNCaP cells according to immunostaining (Fig. 1C). These observations suggest that the expression of CDH2 is increased during the development of enzalutamide resistance.

CDH2 overexpression increases LNCaP and LNCaP EnzaR cell viability. To evaluate the effects of CDH2 on prostate cancer cells, MTT and CCK-8 assays were used to measure cell viability. pCMV-CDH2 plasmid transfection efficiency was confirmed by RT-PCR, which markedly increased CDH2 expression in both LNCaP and LNCaP EnzaR cells compared with that in cells transfected with the empty vector (Fig. S1A).

In the LNCaP cell line, the pCMV-CDH2-transfected cells exhibited the highest levels of cell viability compared with those in the other two control groups 24 h after transfection, according to results from MTT assay (Fig. 2). A similar result




Figure 1. Expression of CDH2 in human PCA cell lines. CDH2 expression was higher in the LNCaP EnzaR cell line compared with that in the LNCaP cell line. (A) RT-PCR analysis of total RNA isolated from LNCaP and LNCaP EnzaR cells. GAPDH served as a loading control. (B) Protein expression of CDH2 in LNCaP and LNCaP EnzaR cells. β-actin served as a loading control. (C) Immunofluorescence assay was used to measure CDH2 expression in LNCaP and LNCaP EnzaR cells. Scale bars, 20 μm. CDH2, N-cadherin; PCA, prostate cancer; EnzaR, enzalutamide-resistant; RT, reverse transcription.




Figure 2. Overexpression of CDH2 increases LNCaP and LNCaP EnzaR cell viability. The OD values are expressed as a percentage of the total number of cells. (A) Cell viability increased significantly in both cell lines overexpressing CDH2 as observed by MTT assay. (B) LNCaP and LNCaP EnzaR cells overexpressing CDH2 also showed increased cell viability. [#]P<0.05 vs. Control and ^{*}P<0.05 vs. pCMV-GFP. CDH2, N-cadherin; PCA, prostate cancer; EnzaR, enzalutamide-resistant; GFP, green fluorescent protein.

was observed in the LNCaP EnzaRA cell line (Fig. 2A). Cell viability was next assessed in the both LNCaP and LNCaP EnzaR cell lines using CCK-8 assay. Cells overexpressing CDH2 also showed the highest levels of cell viability in both LNCaP and LNCaP EnzaR cell lines compared with those in the other two control groups 24 h after transfection (Fig. 2B). These results suggest that CDH2 overexpression can increase PCA cell viability.

CDH2 overexpression increases LNCaP and LNCaP EnzaR cell migration. Ibidi gap closure assays were performed to

examine the cell migratory capacity after transfection. After 24 h of transfection, the migration capacity of untreated LNCaP and LNCaP EnzaR cells was similar to that of empty vector-transfected cells. However, pCMV-CDH2-transfected cells showed a significantly increase in the capacity to migrate towards the center of the well compared with that in cells transfected with the empty vector (Fig. 3). These results were observed in both the LNCaP and LNCaP EnzaR cell lines (Fig. 3).

EMT is known to be associated with cancer cell invasion and migration (13). To clarify the mechanism underlying the increase in cell migration after transfection with




Figure 3. CDH2 overexpression increases LNCaP and LNCaP EnzaR cell migration. Ibidi insert gap closure assays were performed in (A) LNCaP and (B) LNCaP EnzaR cells, (C) which were also quantified. The initial 0 h area was used as a 100% control. Scale bars, 50 μm . * $P < 0.05$ vs. Control; and # $P < 0.05$ vs. pCMV-GFP. CDH2, N-cadherin; EnzaR, enzalutamide-resistant; GFP, green fluorescent protein.

pCMV-CDH2, WB was used to measure the expression of EMT markers E-cadherin, α -SMA, Snail and Slug. α -SMA, Snail and Slug expression are positively correlated, whilst

E-cadherin expression is negatively correlated with EMT (13). The expression pattern of these four markers in untreated cells was similar to that in empty vector-transfected cells, which




Figure 4. Measurement of EMT markers in LNCaP and LNCaP EnzaR cells overexpressing CDH2. Western blot analysis measuring E-cadherin, α -SMA, Snail and slug expression in (A) LNCaP cells and (B) LNCaP EnzaR cells. Transfection with pCMV-CDH2 may increase EMT but not in cells transfected with pCMV-GFP. (C) The expression of E-cadherin was significantly decreased whereas that of α -SMA, Snail and Slug was significantly increased in both cell lines overexpressing CDH2 compared with those in cells transfected with pCMV-GFP. * $P < 0.05$ vs. Control; and # $P < 0.05$ vs. pCMV-GFP. EMT, epithelial-mesenchymal transition; CDH2, N-cadherin; α -SMA, α -smooth muscle actin; EnzaR, enzalutamide-resistant; GFP, green fluorescent protein.

possibly explains the similar cell migratory capacities between these two groups of cells. In pCMV-CDH2-transfected LNCaP and LNCaP EnzaR cells, E-cadherin was significantly down-regulated, whilst the other three markers were significantly upregulated (Fig. 4). This suggests that CDH2 overexpression may induce EMT in LNCaP and LNCaP EnzaR cells, which may be the reason why pCMV-CDH2-transfected cells exhibited the highest cell migration levels. These results suggest that CDH2 overexpression can promote EMT to increase the migratory capacity of PCa cells.

CDH2 knockdown reduces LNCaP and LNCaP EnzaR cell viability. After overexpression, the possible effects of CDH2 knockdown on PCa cells were evaluated. MTT and CCK-8 assays were performed to measure cell viability. siRNA-CDH2 transfection was used to knock down CDH2

expression. siRNA-CDH2 transfection efficiency in LNCaP and LNCaP EnzaR cells was verified using RT-PCR, which markedly reduced CDH2 expression compared with that in cells transfected with siRNA-control (Fig. S1). In terms of the LNCaP cell line, siRNA-CDH2-transfected cells exhibited the lowest levels of cell viability compared with that of the untreated cells and cells transfected with the siRNA-control according to MTT assay (Fig. 5A). In addition, cell viability was significantly reduced by siRNA-CDH2 transfection in the LNCaP EnzaR cell line (Fig. 5A). Similar results were observed according to CCK-8 assay. Specifically, siRNA-CDH2-transfected cells showed the lowest cell viability in both LNCaP and LNCaP EnzaR cells compared with that of the untreated cells and cells transfected with the siRNA-control (Fig. 5B). These results suggest that CDH2 knockdown using siRNA reduced PCa cell viability.




Figure 5. CDH2 knockdown reduces LNCaP and LNCaP EnzaR cell viability. The OD values of MTT and CCK-8 assays are expressed as percentages of the total number of cells. (A) After transfection with siRNA-CDH2, LNCaP cell viability was significantly decreased as according to results from MTT assay. (B) Cell viability was also reduced after transfection with siRNA-CDH2 according to results from CCK-8 assays. * $P < 0.05$ vs. Control; and # $P < 0.05$ vs. siRNA-control. CDH2, N-cadherin; CCK-8, cell counting kit-8; siRNA, small interfering RNA; EnzaR, enzalutamide-resistant.

CDH2 knockdown inhibits LNCaP and LNCaP EnzaR cell migration. According to the Ibidi gap closure assay, it was observed that the level of migration in LNCaP cells transfected with the siRNA-CDH2 was significantly slower compared with that in untreated cells and cells transfected with the siRNA-control after 24 h (Fig. 6A and C). Similar findings were made regarding the levels of LNCaP EnzaR cell migration after 24 h (Fig. 6B and C).

To assess the association between decreased migration capacity and EMT, the protein expression of E-cadherin, α -SMA, Snail and Slug was measured in both LNCaP and LNCaP EnzaR cells by WB. Consistent with this hypothesis, cells with CDH2 expression knocked down appeared to exhibit reduced EMT induction. Specifically, in siRNA-CDH2-transfected LNCaP and LNCaP EnzaR cells, E-cadherin expression was significantly increased, whilst the expression of α -SMA, Snail and Slug was significantly decreased compared with that in untreated cells and cells transfected with the siRNA-control (Fig. 7). These results suggest that CDH2 knockdown can inhibit EMT and EMT-related protein expression to suppress PCa cell migration.

Discussion

In the present study, it was found that CDH2 was expressed at higher levels in LNCaP EnzaR cells compared with that in LNCaP cells *in vitro*. This finding is not unexpected, because CDH2 expression has been previously reported to be increased in poorly differentiated PCa and positively correlate with the Gleason score (26,27,32). Similar observations in terms of the difference in CDH2 expression were obtained by Tanaka *et al* (25) Jennbacken *et al* (33) and Nalla *et al* (34), where androgen-dependent cell lines (LNCaP and LAPC4-AD) and androgen-independent cell lines (LNCaP-19, PC-3 and LAPC4-CR) were assessed.

In terms of cell viability, increased viability was noted after CDH2 overexpression, whereas the opposite was observed after siRNA-CDH2 transfection. This suggests that

CDH2 exerts a key influence on PCa cell survival and proliferation. A similar finding was reported in a previous study by Gao *et al* (35), where microRNA-194 overexpression, which targeted CDH2, was used to regulate PCa cells to reduce cell viability whilst increasing the rate of apoptosis (35). In addition, Wang *et al* (36) performed colony formation assays to explore the effect of CDH2 on the proliferation of PCa cells and demonstrated a positive association between CDH2 expression and PCa cell proliferation (36). Tanaka *et al* (25) also previously showed that N-cadherin-positive LAPC9 cells tended to proliferate more rapidly compared with that in N-cadherin-negative cells (25). The RAS/Raf signaling cascade following the cross-talk of CDH2 with other membrane proteins, such as integrins, may be the cause of tumor cell proliferation (37). However, the underlying mechanism of this was not evaluated in the present study.

Cancer metastasis is a process that requires multiple steps, with migration being a key step (38). In the present study, CDH2 expression in LNCaP cells was found to be associated with cell migration. Using overexpression and gene silencing methods to manipulate CDH2 expression, LNCaP and LNCaP EnzaR cells with higher CDH2 expression were found to have higher migratory capabilities. In previous studies, CDH2 has been frequently reported as a factor that can promote liver, lung, bladder, renal, colorectal, breast, prostate and brain cancer cell migration and metastasis (25,33,36,37). The Rac signaling pathway was found to be one of the underlying mechanistic causes (37). Furthermore, EMT has been found to be highly associated with cell migration (13). Several signaling pathways, including Wnt/ β -catenin, PI3K/AKT, T-cell factor/lymphoid enhancer-binding factor and RhoA, can become activated following cadherin switching (39-43). Crosstalk between these signaling pathways can increase the expression of a number of EMT transcription factors, including Snail, Slug and Twist (39). The increase of EMT transcription factor expression was previously demonstrated in PC3, LNCaP and DU145 cell lines (17,44-45). After determining the interaction between transcription factors, CDH2, EMT and cancer




Figure 6. Knocking down CDH2 expression inhibits LNCaP and LNCaP EnzaR cell migration. After transfection with siRNA-CDH2, images were obtained at 0 and 24 h after wounding. Ibidi insert gap closure assay was performed in (A) LNCaP and (B) LNCaP EnzaR cells, (C) which were then quantified. The 0 h area was used as a 100% control. Scale bars, 50 μm . * $P < 0.05$ vs. Control; and [#] $P < 0.05$ vs. siRNA-control. CDH2, N-cadherin; siRNA, small interfering RNA; EnzaR, enzalutamide-resistant.

cell migration, a possible connection was found between EMT and PCa cell migration by measuring the expression levels of these transcription factors following CDH2 regulation in the present study.

A number of factors and compounds that can target EMT have been previously demonstrated to modulate PCa cells. Li *et al* (46) found that resveratrol can reverse EMT through the Hedgehog pathway in PCa (46). In addition,




Figure 7. Measurement of epithelial-mesenchymal transition markers in PCa cells with CDH2 knockdown. Western blot analysis measuring E-cadherin, α -SMA, Snail and slug expression in (A) LNCaP cells and (B) LNCaP EnzaR cells, (C) which were then quantified. α -SMA, Snail and slug protein expression in cells transfected with siRNA-CDH2 was reduced, whereas E-cadherin expression was increased compared with that in cells transfected with siRNA-control or the control group. * $P < 0.05$ vs. Control; and # $P < 0.05$ vs. siRNA-control. PCa, prostate cancer; CDH2, N-cadherin; α -SMA, α -smooth muscle actin; EnzaR, enzalutamide-resistant; siRNA, small interfering RNA

curcumin was found to inhibit PCa cell EMT and invasion through the monoamine oxidase A/mTOR/hypoxia-inducible factor-1 α signaling pathway (47). MicroRNAs are short, non-coding and single-stranded RNA molecules that have been previously assessed as a potential biomarker in many types of cancer, where they serve a key regulatory functions in PCa progression (48,49). MicroRNA-205, microRNA-143, microRNA-145 have been found to inhibit the EMT process by negatively regulating the expression of several transcription factors (50). Another possible target for PCa inhibition is CDH2. Using overexpression and knockdown approaches, Tanaka *et al* (25) were able to regulate CDH2 expression in the presence or absence of monoclonal CDH2 antibodies and determine its involvement in PCa. After monoclonal antibody inhibition, decreased cell proliferation and invasion *in vitro* and decreased growth and metastasis *in vivo* were observed (25). Similarly, the present study demonstrated that siRNA-CDH2 transfection reduced cell viability and

migration in both LNCaP and LNCaP EnzaR cells *in vitro*. To the best of our knowledge, the present study is also the first to use siRNA for the downregulation of CDH2 expression in EnzaR PCa cells.

The present study is a preliminary study. Therefore, there are a number of limitations. Unlike other studies that used a panel of PCa cell lines, only LNCaP cells were used whereas its subline, LNCaP EnzaR, were used for examination. Furthermore, only *in vitro* experiments were performed to observe the effect of CDH2 knockdown. Since no *in vivo* experiments were performed, the precise mechanism underlying the effects of CDH2 knockdown on prostate tissues could not be verified. The only conclusion that can be drawn from the present study was that PCa cell migration, one of the key steps of metastasis, was impaired as a result of CDH2 knockdown. To further understand the effect of CDH2 knockdown on metastasis, invasion and the extent of mesenchymal-epithelial transition should be examined. In addition,

results in the present study showed that CDH2 expression is positively associated with PCa cell viability, proliferation, migration and EMT. Further studies are warranted to determine the underlying mechanisms. Subsequent experiments should be focused on treating different PCa cell lines and in *in vivo* animal models.

According to the present study, it was demonstrated that EMT served an important role in modulating PCa cell proliferation and migration. In addition, the expression of CDH2, which significantly influences EMT, could be manipulated to reduce PCa cell viability and migration. These findings raise the possibility that CDH2 may be key to controlling CRPC and can be exploited in clinical practice.

Acknowledgements

The authors would like to thank Dr See-Tong Pang (Department of Uro-Oncology, Chang Gung Memorial Hospital, Taiwan), for providing the Enzalutamide-resistant LNCaP cells.

Funding

The present study was supported by E-Da Hospital Research (grant no. NCKUEDA10906) and National Science Council Grants, Taiwan (grant no. MOST 109-2314-B-650-013-MY2).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors' contributions

VCHL and CHO conceived and designed the study. CHL and CHW were the major contributors in writing the manuscript. CHL and PFH analyzed and interpreted the data. CHW, PFH, CYW and WWTK performed the literature review and conducted the experiments. All authors read and approved the final manuscript. VCHL, CHO, CHL and CHW confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Cooperberg MR, Cowan J, Broering JM and Carroll PR: High-risk prostate cancer in the United States, 1990-2007. *World J Urol* 26: 211-218, 2008.
- Pagliariulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN and Studer UE: Contemporary role of androgen deprivation therapy for prostate cancer. *Eur Urol* 61: 11-25, 2012.
- Liu T, Wu LY, Fulton MD, Johnson JM and Berkman CE: Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. *Int J Oncol* 41: 2087-2092, 2012.
- Chandrasekar T, Yang JC, Gao AC and Evans CP: Mechanisms of resistance in castration-resistant prostate cancer (CRPC). *Transl Androl Urol* 4: 365-380, 2015.
- Teo MY, Rathkopf DE and Kantoff P: Treatment of advanced prostate cancer. *Annu Rev Med* 70: 479-499, 2019.
- FDA approves enzalutamide for castration-resistant prostate cancer. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-castration-resistant-prostate-cancer>. Accessed December 1, 2021.
- Wengner AM, Scholz A and Haendler B: Targeting DNA damage response in prostate and breast cancer. *Int J Mol Sci* 21: 8273, 2020.
- Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, *et al*: Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 371: 424-433, 2014.
- Kim YS, Yi BR, Kim NH and Choi KC: Role of the epithelial-mesenchymal transition and its effects on embryonic stem cells. *Exp Mol Med* 46: e108, 2014.
- Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. *Clin Cancer Res* 12: 4147-4153, 2006.
- Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. *Int J Oncol* 31: 277-283, 2007.
- Jennbacken K, Gustavsson H, Welén K, Vallbo C and Damber JE: Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. *Prostate* 66: 1631-1640, 2006.
- Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor metastasis. *Clin Transl Med* 4: 6, 2015.
- Vesuna F, van Diest P, Chen JH and Raman V: Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. *Biochem Biophys Res Commun* 367: 235-241, 2008.
- Vered M, Dayan D, Yahalom R, Dobriyan A, Barshack I, Bello IO, Kantola S and Salo T: Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma. *Int J Cancer* 127: 1356-1362, 2010.
- Randle DD, Clarke S, Henderson V and Odero-Marah VA: Snail mediates invasion through uPA/uPAR and the MAPK signaling pathway in prostate cancer cells. *Oncol Lett* 6: 1767-1773, 2013.
- Uygur B and Wu WS: SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. *Mol Cancer* 10: 139, 2011.
- Navarro P, Ruco L and Dejana E: Differential localization of VE- and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. *J Cell Biol* 140: 1475-1484, 1998.
- Hatta K, Takagi S, Fujisawa H and Takeichi M: Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenetic processes of chicken embryos. *Dev Biol* 120: 215-227, 1987.
- Derycke LD and Bracke ME: N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. *Int J Dev Biol* 48: 463-476, 2004.
- Ma T, Zhao Y, Wei K, Yao G, Pan C, Liu B, Xia Y, He Z, Qi X, Li Z, *et al*: MicroRNA-124 functions as a tumor suppressor by regulating CDH2 and epithelial-mesenchymal transition in non-small cell lung cancer. *Cell Physiol Biochem* 38: 1563-1574, 2016.
- van der Horst G, Bos L, van der Mark M, Cheung H, Heckmann B, Clément-Lacroix P, Lorenzon G, Pelger RC, Bevers RF and van der Pluijm G: Targeting of alpha-v integrins reduces malignancy of bladder carcinoma. *PLoS One* 9: e108464, 2014.
- Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Świerczewska M, Budna J, Kuske A, Gorges TM, Joosse SA, Kroneis T, *et al*: Multiplex gene expression profiling of in vivo isolated circulating tumor cells in high-risk prostate cancer patients. *Clin Chem* 64: 297-306, 2018.

24. Sandig M, Voura EB, Kalnins VI and Siu CH: Role of cadherins in the transendothelial migration of melanoma cells in culture. *Cell Motil Cytoskeleton* 38: 351-364, 1997.
25. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, *et al*: Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. *Nat Med* 16: 1414-1420, 2010.
26. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ and Schalken JA: Cadherin switching in human prostate cancer progression. *Cancer Res* 60: 3650-3654, 2000.
27. Jaggi M, Nazemi T, Abrahams NA, Baker JJ, Galich A, Smith LM and Balaji KC: N-cadherin switching occurs in high gleason grade prostate cancer. *Prostate* 66: 193-199, 2006.
28. Kregel S, Chen JL, Tom W, Krishnan V, Kach J, Brechka H, Fessenden TB, Isikbay M, Paner GP, Szmulewitz RZ and Griend DJV: Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. *Oncotarget* 7: 26259-26274, 2016.
29. Lee GT, Rosenfeld JA, Kim WT, Kwon YS, Palapattu G, Mehra R, Kim WJ and Kim IY: TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. *PLoS One* 14: e0213488, 2019.
30. Pangestu NS, Chueakwon P, Talabnin K, Khiaowichit J and Talabnin C: RNF43 overexpression attenuates the wnt/ β -catenin signalling pathway to suppress tumour progression in cholangiocarcinoma. *Oncol Lett* 22: 846, 2021.
31. Huang YH, Kuo HC, Yang YL and Wang FS: MicroRNA-29a is a key regulator that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation. *Int J Med Sci* 16: 212-220, 2019.
32. Bussemakers MJ, Van Bokhoven A, Tomita K, Jansen CF and Schalken JA: Complex cadherin expression in human prostate cancer cells. *Int J Cancer* 85: 446-450, 2000.
33. Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE and Welén K: N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. *Endocr Relat Cancer* 17: 469-479, 2010.
34. Nalla AK, Estes N, Patel J and Rao JS: N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. *Exp Cell Res* 317: 2512-2521, 2011.
35. Gao S, Zhao Z, Wu R, Wu L, Tian X and Zhang Z: MicroRNA-194 regulates cell viability and apoptosis by targeting CDH2 in prostatic cancer. *Onco Targets Ther* 11: 4837-4844, 2018.
36. Wang M, Ren D, Guo W, Huang S, Wang Z, Li Q, Du H, Song L and Peng X: N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells. *Int J Oncol* 48: 595-606, 2016.
37. Mariotti A, Perotti A, Sessa C and Rüegg C: N-cadherin as a therapeutic target in cancer. *Expert Opin Investig Drugs* 16: 451-465, 2007.
38. Tsai JH and Yang J: Epithelial-mesenchymal plasticity in carcinoma metastasis. *Genes Dev* 27: 2192-2206, 2013.
39. Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. *Cells* 8: 1118, 2019.
40. Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T, Li MC and Lin YH: Role of Wnt/ β -catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1 α . *Int J Urol* 14: 1034-1039, 2007.
41. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH and Li Y: Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. *Cell Death Dis* 4: e875, 2013.
42. Liang J, Li Y, Daniels G, Sfanos K, De Marzo A, Wei J, Li X, Chen W, Wang J, Zhong X, *et al*: LEF1 targeting EMT in prostate cancer invasion is regulated by miR-34a. *Mol Cancer Res* 13: 681-688, 2015.
43. Chen X, Cheng H, Pan T, Liu Y, Su Y, Ren C, Huang D, Zha X and Liang C: mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer. *Mol Carcinog* 54: 1086-1095, 2015.
44. Baygi ME, Soheili ZS, Essmann F, Deezagi A, Engers R, Goering W and Schulz WA: Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. *Tumour Biol* 31: 297-307, 2010.
45. Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, *et al*: A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome. *Oncogene* 38: 913-934, 2019.
46. Li J, Chong T, Wang Z, Chen H, Li H, Cao J, Zhang P and Li H: A novel anti-cancer effect of resveratrol: Reversal of epithelial-mesenchymal transition in prostate cancer cells. *Mol Med Rep* 10: 1717-1724, 2014.
47. Du Y, Long Q, Zhang L, Shi Y, Liu X, Li X, Guan B, Tian Y, Wang X, Li L and He D: Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1 α signaling. *Int J Oncol* 47: 2064-2072, 2015.
48. Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D'Aniello C, Di Franco R, Romano FJ, Montanari M, La Mantia E, Piscitelli R, *et al*: Micrornas in prostate cancer: An overview. *Oncotarget* 8: 50240-50251, 2017.
49. Lo UG, Yang D and Hsieh JT: The role of microRNAs in prostate cancer progression. *Transl Androl Urol* 2: 228-241, 2013.
50. Cochetti G, Rossi de Vermandois JA, Maulà V, Giulietti M, Cecati M, Del Zingaro M, Cagnani R, Suvieri C, Paladini A and Mearini E: Role of miRNAs in prostate cancer: Do we really know everything? *Urol Oncol* 38: 623-635, 2020.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.